Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).
Cesar JiménezMeritxell Ventura-CotsMargarita SalaMargalida CalafatMontserrat García-RetortilloIsabel CireraNuria CañeteGerman SorianoMaría PocaMacarena Simon-TaleroJosé AltamiranoMichael R LuceyGuadalupe Garcia-TsaoRobert S BrownRobert F SchwabeElizabeth C VernaBernd SchnablFrancisco BosquesPhilippe MathurinJuan CaballeríaAlexandre LouvetDebbie Lindsay ShawcrossJuan G AbraldesJoan GenescàRamon A BatallerVíctor VargasPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
Rifaximin is safe in severe AH with a significant reduction in clinical complications. A lower number of infections and a trend towards a lower ACLF and mortality favours its use in these patients.
Keyphrases
- liver failure
- hepatitis b virus
- end stage renal disease
- drug induced
- cardiovascular events
- risk factors
- liver injury
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- cardiovascular disease
- early onset
- type diabetes
- coronary artery disease
- intensive care unit
- extracorporeal membrane oxygenation